Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Escitalopram + sulforaphane is a combination of two agents, escitalopram and sulforaphane, investigated for potential synergistic effects in the treatment of major depressive disorder. Escitalopram is a selective serotonin reuptake inhibitor (SSRI) that increases serotonin levels in the brain by inhibiting its reuptake into presynaptic cells, thereby improving mood and anxiety symptoms[5]. Sulforaphane is an organosulfur compound derived from cruciferous vegetables such as broccoli; it acts primarily as an activator of the Nrf2 pathway, leading to increased antioxidant response and modulation of inflammation[4]. The combination has been studied for enhanced efficacy compared to escitalopram alone in depression management[1].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on escitalopram + sulforaphane.